Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angio-immunoblastic T-cell lymphoma in evolution: a case report.

S Z Usmani1, T Sahay, L Eisenberg

  • 1Department of Medicine, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University, Detroit, Michigan 48235, USA. saadzu@yahoo.com

Advances in Therapy
|September 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Blood cancer journal·2025
Same author

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Leukemia·2017
Same author

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Journal of medical economics·2015
Same author

Insight into human protease activated receptor-1 as anticancer target by molecular modelling.

SAR and QSAR in environmental research·2015
Same author

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

Bone marrow transplantation·2015
Same author

Defining and treating high-risk multiple myeloma.

Leukemia·2015
Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026
Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026
Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026
Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026
Same journal

Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.

Advances in therapy·2026
See all related articles

Angio-immunoblastic T-cell lymphoma (AITL) is a rare non-Hodgkin's lymphoma. Early diagnosis and treatment are crucial, as aggressive forms present with fever and lymphadenopathy, often leading to poor prognosis despite chemotherapy.

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Angio-immunoblastic T-cell lymphoma (AITL) is a rare non-Hodgkin's lymphoma, accounting for 1-2% of cases.
  • AITL typically affects middle-aged and elderly individuals.

Observation:

  • A case study of a patient presenting with high-grade fever and lymphadenopathy is described.
  • Initial diagnostic work-up, including lymph node biopsy, was inconclusive.
  • Symptoms recurred with more pronounced lymphadenopathy, prompting further investigation.

Findings:

  • A second lymph node biopsy revealed changes suggestive of AITL.
  • Flow cytometry confirmed the diagnosis of Angio-immunoblastic T-cell lymphoma.
  • The patient achieved complete remission after the first cycle of hyper-CVAD chemotherapy.

Related Experiment Videos

Implications:

  • AITL has a poor prognosis, particularly with standard chemotherapy regimens.
  • Physicians should consider aggressive lymphomas in patients with unexplained fever and diffuse lymphadenopathy.
  • Prompt and accurate diagnosis is critical for managing AITL and improving patient outcomes.